The importance of measuring IFNβ bioactivity: Monitoring in MS patients and the effect of anti-IFNβ antibodies
- 30 September 2005
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 166 (1-2) , 180-188
- https://doi.org/10.1016/j.jneuroim.2005.06.003
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Mini ReviewHuman Interferons Alpha, Beta and OmegaGrowth Factors, 2004
- Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodiesJournal of Neurology, Neurosurgery & Psychiatry, 2004
- Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosisJournal of Neuroimmunology, 2004
- Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPsBrain, 2004
- Neutralising antibodies to interferon beta during the treatment of multiple sclerosisJournal of Neurology, Neurosurgery & Psychiatry, 2002
- Complex immunomodulatory effects of interferon‐β in multiple sclerosis include the upregulation of T helper 1‐associated marker genesAnnals of Neurology, 2001
- Identification of Critical Residues in Bovine IFNAR-1 Responsible for Interferon BindingPublished by Elsevier ,2001
- Pharmacodynamic Comparison of Single Doses of IFN-beta 1a and IFN-beta 1b in Healthy VolunteersJournal of Interferon & Cytokine Research, 1999
- Characterization of a soluble ternary complex formed between human interferon-β-1a and its receptor chainsProtein Science, 1999
- A Novel Bioassay for the Determination of Neutralizing Antibodies to IFNβ1bJournal of Interferon & Cytokine Research, 1998